N-{2-[ethyl(3-methylphenyl)amino]ethyl}-N'-(2-oxo-1,2,3,4-tetrahydroquinolin-5-yl)-urea | 868593-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-{2-[ethyl(3-methylphenyl)amino]ethyl}-N'-(2-oxo-1,2,3,4-tetrahydroquinolin-5-yl)-urea
• 英文别名: 1-[2-(N-ethyl-3-methylanilino)ethyl]-3-(2-oxo-3,4-dihydro-1H-quinolin-5-yl)urea
• CAS: 868593-16-2
• 化学式: C₂₁H₂₆N₄O₂
• 分子量: 366.463
• InChiKey: LHTFKKAWLUARNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  73.5
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] UREA DERIVATIVES AS ANTAGONISTS OF THE VANILLOID RECEPTOR (VR1)<br/>[FR] DERIVES D'UREE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR VANILLOIDE (VR1)
  申请人：BAYER HEALTHCARE AG

  公开号：WO2005103018A1

  公开（公告）日：2005-11-03

  This invention relates to urea derivatives according to general formula I and salts thereof which are useful as active ingredients of pharmaceutical preparations. The urea derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological disorder or disease, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke; and respiratory diseases and inflammatory disorders such as asthma, chronic obstructive pulmonary (or airways) disease (COPD), common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous irritants such as tobacco smoke, smog, high levels of atmospheric SO2 and noxious gases in the workplace, and airways hyperreactivity, milk product intolerance, Loffler's pneumonia, emphysema, cystic fibrosis, bronchiectasis, pulmonary fibrosis, pneumoconiosis, collagen vascular disease, granulomatous disease, laryngitis, pharyngitis, pneumonia, pleuritis, persistent asthma and chronic asthmatic bronchitis. Formula I Wherein n represents 0, 1, 2, 3, or 4; X represents O, CH2, S, or N(R10), Wherein R10 respresents hydrogen or C1-6 alkyl

  这项发明涉及通式I的尿素衍生物及其盐，它们可作为药物制剂的活性成分。本发明的尿素衍生物作为VR1拮抗剂具有出色的活性，可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗泌尿系统紊乱或疾病，如膀胱过度活动（过度活动膀胱）、尿失禁、神经源性膀胱过度活动（膀胱过度活动）、特发性膀胱过度活动（膀胱不稳定）、良性前列腺增生，以及下尿路症状；慢性疼痛、神经性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风；以及呼吸系统疾病和炎症性疾病，如哮喘、慢性阻塞性肺（或气道）疾病（COPD）、普通感冒、咳嗽、打喷嚏、支气管炎包括急性和慢性支气管炎、支气管炎、鼻炎、过敏性鼻炎、血管运动性鼻炎、粘膜炎、鼻窦炎、过敏、与烟草烟雾、烟雾、工作场所中高水平大气SO2和有害气体等外源刺激物相关的疾病，以及气道过度反应性、乳制品不耐受、洛夫勒肺炎、肺气肿、囊性纤维化、支气管扩张、肺纤维化、尘肺、胶原血管疾病、肉芽肿性疾病、喉炎、咽炎、肺炎、胸膜炎、持续性哮喘和慢性支气管炎。通式I中n代表0、1、2、3或4；X代表O、CH2、S或N(R10)，其中R10代表氢或C1-6烷基。
• UREA DERIVATIVES AS ANTAGONISTS OF THE VANILLOID RECEPTOR (VR1)
  申请人：Bayer HealthCare AG

  公开号：EP1740557A1

  公开（公告）日：2007-01-10